Navigation Links
Advil or Excedrin? New model helps predict product choices
Date:5/30/2008

In today's world, consumers face a dizzying array of product choices. Most often, there's not just one ideal product; it depends on the individual and the context. A beer might be perfect for relaxing after work; a sports beverage after jogging. And a teenager's ideal beverage isn't the same as a business executive's.

A new study in the Journal of Consumer Research shows that multiple ideals can be accurately discovered and then used to predict the preferences of various segments of the population. The authors, Wayne S. DeSarbo (Pennsylvania State University), A. Selin Atalay (Bilkent University, Turkey), David LeBaron, and Simon J. Blanchard (both Pennsylvania State University), developed a model that locates the ideal product in a given situation on a graph.

This new approach has been sorely needed to understand the complexity of how products meet consumers' needs. According to the authors, "Consumers can have more than one ideal product in a given product category. It is therefore essential to understand this aspect of consumer preferences because it can affect how products are promoted to consumers, how new products are designed, and how products are priced and bundled."

The authors used their model to graph the ideal over-the-counter pain relievera $2.1 billion industry with 11 major brands. They identified three groupings of people"price-conscious consumers," "the athletic segment," and "the anti-medication segment." They collected consumers' judgments on the painkillers' effectiveness in various contexts, such as backaches or flu. Using a survey, the model divided up the market into the various segments and showed significant differences among the different consumer types and situations.

For example, price-conscious consumers consider Advil and Tylenol the most effective painkiller overall, but if suffering from a backache, they would be more likely to choose aspirin, or Excedrin for a headache. These differences h
'/>"/>

Contact: Rudy Faust
rfaust@press.uchicago.edu
773-834-0386
University of Chicago Press Journals
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Moonview Sanctuary Releases First Case Study of Client Treated Using Unique Moonview Model
2. Pharsight Invited to Present on Modeling and Simulation at ARCS Australia Scientific Congress
3. Intrabody can mop up mutant protein in Huntingtons disease model
4. Researchers develop first transgenic monkey model of Huntingtons disease
5. Partnership of academic centers and community hospitals effective model for disseminating advances
6. Medsn to Become Indegene Pharmaceutical Solutions, Inc.: Change Signifies the Success of Its Innovative Global Services Model
7. Federation of State Medical Boards Takes Interim Steps Toward Maintenance of Licensure Model Policy
8. Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop
9. Spinal cord injury research hampered by animal models, says new study
10. Versus Technology, Inc. Announces Collaboration with Cleveland Clinic to Create Clinical Patient Flow Model
11. Zimmer Announces New Compliance Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 23, 2014 (HealthDay News) -- Even though its use ... known as Tylenol -- does not help treat lower back ... researchers found the drug was no more effective than a ... lower back pain. Besides showing no effect in easing ... in improving sleep woes tied to back pain, nor did ...
(Date:7/24/2014)... July 24, 2014Malcolm K. Brenner, MD, PhD, Baylor College ... basic and clinical research toward understanding how tumors are ... system, and developing genetically modified T cells that can ... and leadership in the field, Dr. Brenner is the ... Therapy , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:7/24/2014)... 2014 Becker's Hospital Review has published ... Health Systems With Great Oncology Programs." Organizations on this ... quality patient care, cancer outcomes and research. , The ... based on rankings and awards they have received from ... considered as part of the criteria for inclusion on ...
(Date:7/24/2014)... 24, 2014 "North America Spinal ... data on the North America Spinal Surgery market. ... dollars, and volume (in units) and average price ... Fusion, Vertebral Compression Fracture Repair Devices and Spinal ... America Spinal Surgery Market:,     Medtronic, ...
(Date:7/24/2014)... 2014. LSE Health and the European Heart Academy ... are pleased to announce the launch of a ... the field of cardiovascular sciences. , The MSc ... Sciences aims to equip cardiovascular specialists with the ... to take on advisory, management or leadership roles ...
Breaking Medicine News(10 mins):Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3Health News:Malcolm K. Brenner receives Pioneer Award for advances in gene-modified T cells targeting cancer 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 3Health News:100 Hospitals, Health Systems With Great Oncology Programs 4Health News:Spinal Surgery Market in North America Forecast to 2020 New Report Available at ReportsnReports.com 2Health News:Spinal Surgery Market in North America Forecast to 2020 New Report Available at ReportsnReports.com 3Health News:Spinal Surgery Market in North America Forecast to 2020 New Report Available at ReportsnReports.com 4Health News:LSE and ESC announce the launch of a new executive-style MSc 2
... cabinet, may help in easing out prostate problem, according to ... known to help in the prevention of arthritic inflammations, heart ... The researchers say that now it may help solve some ... enlarged prostates. ,It may help reduce the urinary ...
... view of The Sterling Council, of levying ?1 a week for ... refuses to buy. The complainant, Mrs. C, has not minced words ... the society, and truly a mockery of the free care provided ... emergency care system in her home in 2002. This allowed emergency ...
... of the University of Sao Paulo Medical School in Brazil ... getting the best care in case of chronic coronary artery ... to be published in the September edition of the Journal ... to receive their physician-recommended treatment showed a significantly lower incidence ...
... A British tourist in Hong Kong is suspected of having the ... been named and was admitted to a Hog Kong hospital// after ... man came to the country on April 4 and was admitted ... Chinese origin and underwent intestinal surgery earlier. Hong Kong health department ...
... A $500,000 television and radio ad campaign blaming GOP ... prescription drug program has been launched by the// Association ... ,The ad campaign accusing the lawmakers for blocking provisions ... companies for the best prescription cost has been targeted ...
... techniques and concussions among high school athletes found that ... of// concussion. ,In the current ... Medicine in Philadelphia and co-author Dr. Tracey Covassin of ... directors of athletics from Pennsylvania and New Jersey high ...
Cached Medicine News:Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 3Health News:Ad Campaign Targeting Republicans On Medicare Prescription Drug Program 2Health News:Proper Fitting Of Football Helmets Essential To Prevent Concussion 2
(Date:7/24/2014)... 24, 2014 Lpath, Inc. (NASDAQ: ... lipid-targeted therapeutics, reported interim results in a Phase ... investigated as a treatment for metastatic renal cell ... least one therapy involving a VEGF inhibitor (e.g., ... mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of ...
(Date:7/24/2014)... N.J., July 24, 2014 , Revenues ... year , Adjusted diluted EPS from continuing operations of ... EPS from continuing operations of $0.92, 7% below prior year ... versus prior year , Full year 2014 revenues now ... to 4% previously , Full year 2014 adjusted diluted ...
(Date:7/24/2014)... HIGHLIGHTS:Q2 2014 Results (all percentage changes ... sales increased 3% to $701 million.  Sales grew organically by ... percentage point to sales growth. , By business unit, ... and 1% in SAFC Commercial. , Reported diluted EPS ... of 13%.  Adjusted diluted EPS in Q2 2014 was also ...
Breaking Medicine Technology:Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12
... CAMPBELL, Calif., Oct. 14, 2011 EMKinetics, Inc. ... System pivotal trial for patients suffering ... trial will be conducted at 10-15 US centers. ... follow the completion of the study.   EMKinetics, ...
... The Better Hearing Institute (BHI) is warning ... one-size-fits-all hearing aids instead of consulting a hearing healthcare ... serious underlying medical problem. All 50 states require that ... hearing aids. BHI also points out that ...
Cached Medicine Technology:EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System 2Better Hearing Institute Warns on Do-It-Yourself Hearing Care 2Better Hearing Institute Warns on Do-It-Yourself Hearing Care 3
... EX.P.R.T. Release Technology essentially eliminates premature ... Unique anatomically designed tapered stent for ... 0.014 Rapid Exchange catheter with 6 ... atraumatic tip,, Radiopaque marker on catheter ...
... blood hematology control manufactured specifically for the ... the Coulter AcT5diff instruments. The composition of ... differential, positioning the populations within the limitations ... product offers 105-day closed-vial stability and 14-day ...
... a whole blood control for evaluating the ... measure automated blood cell counts in patient ... RBC and WBC values for the Abbott ... LH750/LH 755 (levels 2 and 3 only) ...
... is a gene expression ... the risk of metastasis ... It is based on ... the Netherlands Cancer Institute ...
Medicine Products: